within Pharmacolibrary.Drugs.ATC.A;

model A07AA12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.018,
    Cl             = 0.00021666666666666666,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.046,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 9.96
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07AA12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fidaxomicin is a narrow-spectrum macrocyclic antibiotic used primarily for the treatment of Clostridioides difficile-associated diarrhea. It is approved for use in adults and children and exhibits minimal systemic absorption, acting mainly in the gastrointestinal tract.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Louie, TJ, et al., &amp; Shue, YK (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. <i>The New England journal of medicine</i> 364(5) 422–431. DOI:<a href=\"https://doi.org/10.1056/NEJMoa0910812\">10.1056/NEJMoa0910812</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21288078/\">https://pubmed.ncbi.nlm.nih.gov/21288078</a></p></li><li><p>Tashiro, S, et al., &amp; Matsumoto, K (2023). Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models. <i>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</i> 29(5) 616–622. DOI:<a href=\"https://doi.org/10.1016/j.cmi.2022.12.015\">10.1016/j.cmi.2022.12.015</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36574949/\">https://pubmed.ncbi.nlm.nih.gov/36574949</a></p></li><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2015). Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection. <i>The Canadian journal of infectious diseases &amp; medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale</i> 26(6) 305–312. DOI:<a href=\"https://doi.org/10.1155/2015/934594\">10.1155/2015/934594</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26744587/\">https://pubmed.ncbi.nlm.nih.gov/26744587</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07AA12;
